Theodore Hook

Theodore Hook

Theodore Hook, the son of James Hook, the musical composer, was born in London on 22nd September, 1788. He was educated at Harrow School, where, according to his own account, principally distinguished himself for mischief and deceptiveness.

At the age of sixteen Theodore and his father began working together on musicals, including the successful Soldier's Return. Although ridiculed by Lord Byron, these comic operas were extremely popular with the public.

In 1813 Hook used his contacts to acquire the post of the account-general of Mauritius. Four years later allegations were made against Hook and an investigation showed that 62,000 dollars were missing. Hook's property was seized and was imprisoned for two years.

When Hook was released he returned to writing. With the help of Sir Walter Scott, Hook was made editor of John Bull, a Sunday newspaper. Hook very patriotic paper that was highly critical of the Whigs. At the time the newspaper was described as "scurrilous, scandalous, but irresistibly facetious".

Hook continued to edit the John Bull newspaper for 21 years. He also wrote several novels including Maxwell (1830), The Parson's Daughter (1832), Love and Pride (1832), Gilbert Gurney (1836), Gurney Married (1838) and Births, Marriages and Deaths (1839).

Theodore Hook remained deeply in debt and when he died on 24th August, 1841, his property was seized by the crown.


History of postcards

Tracing back the origins of the picture postcard is difficult because postcards were not simply invented — instead, they evolved. Their history is inevitably linked with the development of the postal service, but also features innovations in printing and photography, daring proposals. and even a 300-meter tower!

We try to chronicle the history of postcards through a timeline of relevant events, going back a few centuries to provide the context that culminated in postcards being officially issued and recognized by a postal operator, on October 1st 1869.

17-19th century

Following the popularization of printing presses, visiting cards, bill heads, writing paper and other types of paper ephemera started to have illustrations on them, often with delicate engravings and tasteful designs.

Already in 1777, French engraver Demaison published in Paris a sheet of cards with greetings on them, meant to be cut and sent through the local post, but people were wary of servants reading their messages. so the idea was not very well received.

A postal reform in the UK unified the cost of domestic mail delivery to 1 penny per envelope, to be prepaid by the sender. The proposals of Sir Rowland Hill also included that the pre-payment was to be made by issuing printed sheets of adhesive stamps. The Penny Black, the world's first adhesive postage stamp, made its debut in May 1840.

Simultaneously, decorated prepaid letter sheets (similar to today's aerograms) were also put on sale by the post office. These were designed by William Mulready and showed Britannia with a lion at her feet, sending mail messengers to all parts of the world. Though this particular design turned out to be unpopular and often ridiculed, this was the first postal stationery item issued by the post office that had decorations on the outside. They were replaced the following year by plain pink envelopes, with a printed 1 penny stamp on the corner.

Already that year, Theodore Hook Esq, a British writer, mailed himself a caricature of post office workers, shown to be writing mail in order to sell more stamps. Most likely mailed as a joke (and delivered against the post office regulations of the time), this could probably be the earliest record of a postcard being sent through the mail.

A few years later, in 1843, Sir Henry Cole produced the first Christmas greeting card, a drawing of himself and his family. This was the year in which Charles Dickens A Christmas Carol was published.

In late February, the US Congress passed an act that allowed privately printed cards, weighing one ounce or less, to be sent in the mail.

Later that year, John P. Charlton from Philadelphia patented a postal card and sold the rights to Hymen Lipman (founder of the first envelope company in the US and inventor of the lead-pencil and eraser). However, with the start of the Civil War a month later, these Lipman Cards as they became known were forgotten and not used until almost a decade later.

The earliest record of Lipman card's being used is from October 25, 1870, sent from Richmond, Indiana. It featured an illustrated advertisement of Esterbrook Steel pens, and was the first pictorial postcard to be mailed in the USA.

At the Karlsruhe postal conference, Heinrich von Stephan proposed the creation of offenes Postblatt (or, open post-sheets). The goal was to simplify the etiquette of the letter format, but also to reduce the work, paper and costs involved in the sending of a short message.

He suggested the introduction of a rigid card, roughly the size of an envelope, which could be written on and mailed without the need for an envelope, having the postage pre-printed.

The idea was not so well received in Germany: the post office feared the complexity and cost of implementing the scheme in all the different states, each emitting their own stamps.

Despite this setback, Von Stephan was a prominent figure in the history of postal services in Germany. Beginning his work as a postal clerk in 1849, he was successively promoted until he reached the post of Minister of Postal Services in 1895. He focused on the standardization and internationalization of postal services, and later helped establish the Universal Postal Union.

1st October 1869

In Austria-Hungary, Dr. Emanuel Herrmann (a professor of Economics from Vienna) wrote an article in the Neue Freie Presse pointing out that the time and effort involved in writing a letter was out of proportion to the size of the message sent. He suggested that a more practical and cheaper method should be implemented for shorter, more efficient communications.

His recommendations impressed the Austrian Post, who put them to practice on October 1st 1869, resulting in the Correspondenz-Karte, a light-brown 8.5x12cm rectangle with space for the address on the front, and room for a short message on the back. The postcard featured an imprinted 2 Kreuzer stamp on top right corner, costing half the price of a normal letter.

It is not known whether Dr. Herrmann had any knowledge of Von Stephan's earlier proposal for a very similar card.

Seeing the immense popularity of this new means of communication, Switzerland, Luxembourg, the United Kingdom and some states of Germany quickly followed suit, issuing postcards less than a year after the initial launch.

Belgium, Holland, Denmark, Finland, Sweden, Norway, and Canada issued cards in 1871, and the following year also Russia, Chile, France, and Algeria added postcards to their offers. In 1873, France, Serbia, Romania, Spain, Japan and the United States issued their own postcard offerings. By 1874, Italy, Romania and Serbia had also began to issue theirs.

The General Postal Union (later renamed Universal Postal Union) was created in Bern, Switzerland. One of its first postal treaties fixed a standard postage for letter mail sent to the members of the Union, and determined that half that rate should be applied to postcards.

This made sending postcards abroad much cheaper, and less complicated.

Today, the UPU is a specialized United Nations agency that coordinates postal policies among its 192 members, standardizing procedures and making international mail delivery much simpler. Prior to its establishment, each country had to organize separate treaties with every single country to engage in international mail delivery with them.

In 1894, twenty years after its inception, an estimated 1.7 billion postcards were exchanged between UPU member countries.

1880s

In the 1880s, many postcards were printed with small sketches or designs (called vignettes) on the message side, initially just in black, but increasingly also in color. Slowly, Germany came to dominate the industry of chromolithography, with many postcards being printed there. A large number of these featured illustrated views of a town and the expression Gruss Aus (or, Greetings from), leaving enough space for a message.

At the end of the decade, the Eiffel Tower made its debut on the Exposition Universelle of 1889 that took place in Paris. French engraver Charles Libonis designed postcards for the occasion featuring the monument, which was the tallest tower in the world at the time. The novelty postcards, which could be mailed from the Eiffel Tower itself, were much beloved by the visitors and became known as Libonis.

1890s

The 1890s saw photography starting to be used in postcards, gradually increasing in popularity over the next few decades. All matter of subjects were photographed with topographics (urban street scenes and general views) being a recurrent topic.

At the turn of the century, Kodak launched the No. 3A Folding Pocket camera with negatives that were the same size as postcards, and could thus be printed directly onto postcard card stock without cropping, keeping it simple.

Already in 1854, French photographer Andre Disdéri had patented a version of the photographic carte de visite, which proved to be incredibly popular as visiting cards. They could be reproduced inexpensively and in large quantities, and had space on the back to write a note. Visiting or calling cards could be given out in person or when making social calls, and were incredibly popular in Europe and the United States.

The World's Columbian Exposition opens in Chicago, a world fair where 46 nations participated with exhibitions and attractions. Over 26 million people visited the fair, and for many of them, this was a once-in-a-lifetime chance to discover what lies beyond their own country's borders.

Publisher Charles W Goldsmith seized the opportunity to produce a novelty set of official postcards, showing the pavilions and other interesting sections of the exhibition in color. These were the first commercially produced pictorial postcards to be printed as a souvenir in the United States, and they proved to be a sensational hit.

A year later, prominent London journalist James Douglas wrote:

"Like all great inventions, the Picture Postcard has wrought a silent revolution in our habits. It has secretly delivered us from the toil of letter-writing. There are men still living who can recall the days when it was considered necessary and even delightful to write letters to one's friends. Those were times of leisure. (. ) Happily, the Picture Postcard has relieved the modern author from this slavery. He can now use all his ink in the sacred task of adding volumes to the noble collection in the British Museum. Formerly, when a man went abroad he was forced to tear himself from the scenery in order to write laborious descriptions of it to his friends at home. Now he merely buys a picture postcard at each station, scribbles on it a few words in pencil, and posts it. This enhances the pleasures of travel.
Many a man in the epistolary age could not face the terrors of the Grand Tour, for he knew that he would be obliged to spend most of his time in describing what he saw or ought to have seen. The Picture Postcard enables the most indolent man to explore the wilds of Switzerland or Margate without perturbation. "

In June of 1897, the World Association Kosmopolit was founded in Nuremberg, a postcard collecting club with thousands of members. They would send postcards to each other with the greeting Gutferngruß, requesting a return card to be mailed back, thus collecting postcards from all over the world.

The association was active until the First World War, and at its peak counted with more than 15 000 members in Germany alone.

1900-1915

The turn of the century saw the golden era of postcards. An article on the Standard (a British newspaper) from August 21, 1899 read:

With multiple daily pickups and deliveries (up to 12 times per day in large cities!), postcards were effectively the text messages of their time. It was cheap and convenient to send them, and postcard-obsession reached its peak in the Edwardian era with billions of them being sent every year.

Scenic landscapes, portraits, exhibitions, royal visits, humorous scenes or even current events were quickly printed in postcards shortly after taking place. The many surviving examples of such postcards tell a vivid picture of the time.

On August 21, 1899, an article on the British newspaper Standard read:

"The illustrated postcard craze, like the influenza, has spread to these islands from the Continent, where it has been raging with considerable severity. Sporadic cases have occurred in Britain. Young ladies who have escaped the philatelic infection or wearied of collecting Christmas cards, have been known to fill albums with missives of this kind received from friends abroad but now the cards are being sold in this country, and it will be like the letting out of waters.(. )"

"Germany is a special sufferer from the circulation of these missives. The travelling Teuton seems to regard it as a solemn duty to distribute them from each stage of his journey, as if he were a runner in a paper chase. His first care on reaching some place of note is to lay in a stock, and alternate the sipping of beer with the addressing of postcards. Sometimes he may be seen conscientiously devoting to this task the hours of a railway journey. Would-be vendors beset the traveller on the tops of hills, and among the ruins of the lowlands, in the hotel, the café and even the railway train. They are all over the country, from one end of the Fatherland to the other, — from the beech woods of Rügen on the North, to the southernmost summit in the Saxon Switzerland. Some of these cards, by the way, are of enormous size and anyone who is favoured with them by foreign correspondents is subjected to a heavy fine by the inland postal authorities, who are not content with delivering them in a torn and crumpled state."

In 1902, the British Post Office allowed messages to be written on one half of the side normally reserved for the address, paving the way for the divided back era of postcards. This left the reverse side of the card free to be completely filled with an image.

However, these postcards could not be sent abroad until other Universal Postal Union members agreed to do the same. An agreement on the matter was reached at the Sixth Postal Union Congress in Rome, in 1906.

An American of German descent, Curt Teich started a publishing company in Chicago in 1898 focused on newspaper and magazine printing. A few years later, in 1908, Curt Teich Co. introduced postcards to their portfolio, and over the next few decades became the world's largest printer of view and advertising postcards.

Curt Teich was an early pioneer of the offset printing process, and the first to understand the advantages of using lightly embossed paper to speed up the drying of ink, allowing the finished product to retain brighter colors. Because of their texture resembling linen, these embossed postcards became known as linen cards.

He is best known for the Greetings From postcards with large letters, having successfully adapted the idea of the earlier Gruss Aus cards to the US audience.

1908 was also the year in which E. I. Dail, a salesman from Michigan, invented the revolving postcard rack. The metal contraption could be placed in a counter and allowed customers to view and select postcards for themselves.

Starting in 1913 and well into the 1930s, postcards featuring a white border became commonplace in the US.

Typically, multiple postcards were printed in rows on a large sheet of paper, which had to be trimmed around the edges of each postcard — a job that required a great deal of precision. The white borders were introduced to give some margin of error to the process, thus making them less expensive to produce.

The expression carte-maximum (maximum card or maxicard) was first used in 1932, when a collector named Lecestre published an article on Le Libre Échange detailing the design of this philatelic item. A maxicard consists of picture postcard with a postage stamp and a cancellation mark affixed on the picture side of the card. The themes of all these three elements should match in terms of motives, time and location, so that they are in "maximum concordance".

The study, creation and collection of maximum cards is called maximaphily.

On July 14, 2005 Postcrossing was launched!

The website platform was built by Paulo Magalhães, a Portuguese software engineer who loved receiving postcards but did not know many people he could exchange them with. So he coded a website on his free time with the goal of connecting him with other people who also enjoyed sending and receiving postcards. What started as a small side project quickly became a worldwide hobby, shared by many postcard enthusiasts. To date, over 57 million postcards have been exchanged through the platform, with thousands more on the way.

On the 150 th anniversary of the postcard, Postcrossing organized a worldwide campaign to celebrate the special ocasion.

A postcard contest received thousands of submissions from all over the world sharing their enthusiasm for postcards, filled with kind and thoughtful messages.

A selection of some of the best postcards was showcased during October in an exhibition at the Universal Postal Union headquarters in Bern, Switzerland. More details of the exhibition can be found on Postcrossing's blog.

Many postal operators, museums, libraries and event schools joined the celebrations with postcard related events and initiatives.

  • 58 meetups
  • 11 postcard exhibitions
  • 8 special cancellation marks
  • 8 workshops
  • 6 seminars
  • 4 commemorative postcards issued by post offices
  • 3 guided tours
  • 2 postage stamps

After a successful celebration in 2019 of the 150th anniversary of the postcard, Postcrossing, with the help of Finepaper, decided to launch the World Postcard Day on every October 1st — a day to celebrate the postcard and the connections it brings.

A postcard design contest was organized among design&art students to create an official postcard for the event that was made available for everyone to use on this date.

In the midst of a very unusual year, the special day was nonetheless comemorated all over the world, with the issue of comemorative postcards, dedicated cancellation marks, events in schools, philately fairs, libraries, museums, discounts at post offices and, above all, many many postcards.


Return Engagement: A Stupendous Regency Prank by Theodore Hook, 1809

We might have missed April Fools' Day earlier this week, but we haven't forgotten it! Here's one of our favorite posts from the past about a prank that's justifiably famous. Some historians now question whether it actually took place at all, or was simply another form of hoax foisted on the press by the perpetrators either way, it still makes for an outrageous story.

April Fools' Day deserves a rascal, and today we're offering this disarming young fellow, left, as a Regency rascal extraordinaire. Theodore Edward Hook (1788-1841) was to become a writer, playwright, & financial finagler. But in 1809, he was a twenty-one-year-old known for his outrageous wit, mischief, and audacity, newly freed from school and ready to concoct the prank that made him famous.

For grievances now long forgotten, he decided a Mrs. Tottenham deserved to be his victim. With two friends as accomplices, he spent six weeks sending out hundreds of fake invitations to famous folk (among those who innocently appeared were the Lord Mayor of London, the Duke of Gloucester, and the chairman of the East India Company) and orders for goods and services to scores of tradesmen. Then, on the appointed day, he and his friends sat in a room across the street from the unfortunate Mrs. Tottenham's house and watched the mayhem they'd created in this quiet residential neighborhood. Here's how it was reported in a London newspaper at the time:

A HOAX.- This very malignant species of wit was yesterday most successfully practised at the house of Mrs. T––, a lady of fortune, at No. 54, Berners-street, which was beset by about three dozen tradespeople at one time, with their various commodities, and from the confusion altogether, such crowds had collected as to render the street impassable. Waggons laden with coals from the Paddington wharves, upholsterers' goods in cart-loads, organs, pianofortes, linen, jewellery, and every other description of furniture, were lodged as near as possible to the door of No. 54, with anxious tradespeople and a laughing mob. About this time, the Lord Mayor arrived in his carriage, but his lordship's stay was short, and he was driven to Marlborough-street police-office. At the office, his lordship informed the sitting magistrate that he had received a note purporting to come from Mrs. T––, which stated that she had been summoned to appear before him, but that she was confined to her room by sickness, and requested his lordship would do her the favor to call on her. Berners-street was, by this time, in the greatest confusion, by the multiplicity of tradespeople, who were returning with their goods, and spectators laughing at them. The officers at Marlborough-street office were immediately ordered out to keep order, but it was impossible. The first thing witnessed by the officers was six stout men bearing an organ, surrounded by wine-porters with permits, barbers with wigs, mantua-makers with band-boxes, opticians with the various articles of their trade, and such was the pressure of tradespeople who had been duped, that at four-o'clock all was still confusion. The street was not cleared at a late hour, as servants wanting places began to assemble at five o'clock. besides a coffin which was brought to Mrs. T––'s house, made to measure. there were accoucheurs, tooth-drawers, miniature painters, and artists of every description.

While this elaborate prank angered most of the unwitting participants, it amused a great many others, and was widely written about and discussed. Hundreds of people had been involved, and a "quarter of the town disturbed." Although Hook was suspected, nothing could be proved against him, and he gleefully escaped any punishment. Nowadays we're sure it would have landed him his own show on MTV.

Above: Theodore Hook, artist unknown, c. 1808. From The Life & Remains of Theodore Edward Hook .

5 comments:

I am on the side of the angered. I haven't changed my mins since I first rread about this but had managed to put it out of my mind. I hate practical jokes which are seldom practical or true jokes.
If the work was calledx a bit of spite or revenge or how to humiliate XYZ it would more clearly show my opinion of it.

Hook certainly seems to have been the kind of heartless wit that was often admired, from a safe distance, at that time. If I were Mrs. Tottenham, I might have bided my time and tried to return the favor at some point. Looking at his life, however, I doubt she could have done much to him that was worse than what he did to himself.

How truly unbelieveable- not particularly amusing, but quite incredible in its scope. I sure am glad he's not still around.

Love it. Like ordering dozens of pizzas to be delivered to someone you hate.

I'm on the side of angered as well. Not only a problem for the one victim, but costing many other people time and money as well. I'd like to see a nice jail sentence for this along the lines of disturbing the peace, and the perpetrator being financially responsible for the costs to the tradespeople and anyone else damaged by this, like the residents who might not have been able to get to their jobs, appointments, doctors' offices.


Darkness Visible: A Farce in Two Acts Performed with Great Applause at the Theatre Royal: Written by Theodore Edward Hook, Esq

Nineteenth Century Collections Online: European Literature, 1790-1840: The Corvey Collection includes the full-text of more than 9,500 English, French and German titles. The collection is sourced from the remarkable library of Victor Amadeus, whose Castle Corvey collection was one of the most spectacular discoveries of the late 1970s. The Corvey Collection comprises one of Nineteenth Century Collections Online: European Literature, 1790-1840: The Corvey Collection includes the full-text of more than 9,500 English, French and German titles. The collection is sourced from the remarkable library of Victor Amadeus, whose Castle Corvey collection was one of the most spectacular discoveries of the late 1970s. The Corvey Collection comprises one of the most important collections of Romantic era writing in existence anywhere -- including fiction, short prose, dramatic works, poetry, and more -- with a focus on especially difficult-to-find works by lesser-known, historically neglected writers.

The Corvey library was built during the last half of the 19th century by Victor and his wife Elise, both bibliophiles with varied interests. The collection thus contains everything from novels and short stories to belles lettres and more populist works, and includes many exceedingly rare works not available in any other collection from the period. These invaluable, sometimes previously unknown works are of particular interest to scholars and researchers.

European Literature, 1790-1840: The Corvey Collection includes:

* Novels and Gothic Novels
* Short Stories
* Belles-Lettres
* Short Prose Forms
* Dramatic Works
* Poetry
* Anthologies
* And more

Selected with the guidance of an international team of expert advisors, these primary sources are invaluable for a wide range of academic disciplines and areas of study, providing never before possible research opportunities for one of the most studied historical periods.

Primary Id: B0054700
PSM Id: NCCOF0063-C00000-B0054700
DVI Collection Id: NCCOC0062
Bibliographic Id: NCCO000919
Reel: 76
MCODE: 4UVC
Original Publisher: Printed for C. Chapple
Original Publication Year: 1817
Original Publication Place: London


Personal Life and Death

Hooke never married. His niece, Grace Hooke, his longtime live-in companion and housekeeper, as well as his eventual lover, died in 1687 Hooke was inconsolable at the loss.

Hooke&aposs career was marred by arguments with other prominent scientists. He often sparred with fellow Englishman Isaac Newton, including one 1686 dispute over Hooke’s possible influence on Newton’s famous book Principia Mathematica.

In his last year of life, Hooke suffered from symptoms that may have been caused by diabetes. He died at the age of 67 in London on March 3, 1703.


Fairies, rabbit births and an ‘ancient’ tiara: what are the greatest historical hoaxes?

From the 'Rabbit Woman of Godalming' to a fake treasure that fooled the Louvre and Adolf Hitler's diaries, BBC History Revealed rounds up the some of the most successful cons, swindles and hoodwinks that have made the history books

This competition is now closed

Published: April 1, 2020 at 12:55 pm

The Cottingley Fairies

In 1917, as two young cousins, Elsie Wright and Frances Griffiths, played with a camera in Cottingley, near Bradford, they shot a series of garden photos with fairies in them. Elsie’s mother was the first to believe in the snaps’ authenticity – but she wasn’t the last. The images were declared genuine by experts and the ‘Cottingley Fairies’ fast became recognisable the world over.

It wasn’t until the 1980s that the cousins confessed to their trickery – the fairies were actually drawings by Elsie, secured in the ground with hatpins – but they still claimed one photo was real.

The Berners Street Hoax

One of the most ambitious hoaxes of all time kicked off at 5am on 27 November 1810, when a chimney sweep arrived at 54 Berners Street, London. The resident, Mrs Tottenham, hadn’t called for one.

For the rest of the day, the house was bombarded by a stream of merchants, tradesmen and dignitaries. There were bakers, butchers, brewers, mongers, wig makers, upholsterers, gardeners, chefs and cobblers.

Deliveries flooded in of food, furniture, pianos and a pipe organ. Then came the doctors, apothecaries, lawyers and a line of London’s elite – including the governor of the Bank of England, the Archbishop of Canterbury and the Lord Mayor. The police only stopped the mayhem by closing the street.

Behind it all was Theodore Hook, who had bet a friend he could make any house the most talked about spot in London. He sat in a house opposite number 54 and watched the carnage unfold.

The Tiara of Saitaferne

In April 1896, the Louvre museum, Paris, had just made its latest acquisition: a golden, Greco-Scythian crown. The Louvre snapped up the tiara for 200,000 francs, believing it to have been a Greek gift to the Scythian King Saitaphernes, and that it dated from the third century BC.

In fact, it was just one year old. A close inspection found traces of modern tools and soldering. The Louvre still owns the crown (but don’t expect to see it on display).

The woman who gave birth to rabbits

In 1726, a young woman from the Surrey town of Godalming caused a medical sensation, baffling physicians with her unusual condition. Mary Toft convinced a number of doctors that, after seeing a large rabbit while pregnant, she had given birth – over a period of time – to a litter of the creatures. John Howard, a local surgeon and midwife, attended some of the so-called bunny births and believed her story.

He informed a number of eminent medics, including the surgeon to King George I’s royal household Nathaniel St Andre, who went on to examine some of the animal parts that Toft had claimed to have given birth to. He concluded that Toft’s case was genuine. But a second royal surgeon, Cyriacus Ahlers, was decidedly sceptical, leading to Toft being intensely questioned in London.

Finally, after threats of a “very painful experiment”, Toft confessed that the whole thing was a hoax. She had faked the births by stuffing the animal parts inside herself, although what motivated her to do so is unclear. She was imprisoned, but soon released to live out the rest of her days in Godalming, known as the ‘Rabbit Woman’. Satirists and pamphleteers had a field day, and St Andre’s career never fully recovered from the abject humiliation.

Turning lead into gold

Alchemy – the pseudo-science of turning ordinary metals into gold – attracted its fair share of charlatans. One notably outrageous scheme came from an alchemist for Duke Cosimo I of Florence, Italy. In 1555, the trickster secretly created an unrecognisable substance out of gold, which he called ‘usufur powder’, and distributed it to local apothecaries. He then announced to the Duke that he could make gold out of some basic items, including the mysterious usufur.

The ingredients were brought to him and the experiment was a success. Amazed, the Duke coughed up some 20,000 ducats for the recipe, before the canny con man hightailed it to France, leaving no usufur behind.

The (fabricated) Donation of Constantine

An important hoax of the Middle Ages, The Donation of Constanine is a document that supposedly records the gift of vast amounts of land from the Roman Emperor, Constantine the Great, to Pope Sylvester I in the fourth century AD. The false text – which actually dates from the eighth century AD – tells the story of the Emperor’s conversion to Christianity, and how the Pope cured him of leprosy, as well as the gift. The Donation had great influence on the politics and religion of medieval Europe, until it was proved a forgery in the 15th century.

Hitler’s diaries

In 1983, German newspaper Stern published an explosive exclusive: Adolf Hitler’s diaries. But this was one story that blew up for all the wrong reasons. Within two weeks, the journals were exposed as sophisticated forgeries. It seems that, desperate to prevent a leak and protect their £2.5 million investment, Stern officials had refused to let any German World War II experts inspect the 60 handwritten volumes before they went to press. But soon historical inaccuracies were spotted, and the series was exposed as the creation of antiques dealer and painter Konrad Kujau.

The Piltdown Man

One of the greatest hoaxes in the history of science, the mystery behind the Piltdown Man is still unsolved. When the remains of Eoanthropus dawsoni were discovered in East Sussex in 1912, it was thought the evolutionary link between humans and apes had been found.

It wasn’t till 1953 that the bones were truly identified as an amalgamation. An orangutan jaw had been patched onto a human skull.

Napoleon’s premature demise

A man walks into a Dover pub declaring “Napoleon is dead!” It may sound like the start of a bad joke but, in fact, it’s a swindle. News of the Emperor’s demise flew through 1814 Britain, as it meant war with France was over. In truth, Napoleon wasn’t dead at all. But as the promise of peace grew, the stock market boomed. As a result, three people made a killing on very-recent investments. They were subsequently found guilty of fraud.

A chess supercomputer… in the 18th-century

A chess-playing machine with the uncanny ability to beat almost everyone it plays? Surely such things didn’t exist until the 20th century? Well, yes, but those who saw The Turk in the 18th century would beg to differ. They saw a mechanical man, seated in front of a cabinet, who could play a blinding game of chess, and it looked like real artificial intelligence.

Inside the cabinet was a complex clockwork mechanism and, unbeknown to audiences, a gifted chess player, hidden from view. The Turk was a sensation for 50 years – after its debut in Vienna, 1770, it went on a tour of Europe.


Theodore Hook - History

No portrait survives of Robert Hooke. His name is somewhat obscure today, due in part to the enmity of his famous, influential, and extremely vindictive colleague, Sir Isaac Newton. Yet Hooke was perhaps the single greatest experimental scientist of the seventeenth century. His interests knew no bounds, ranging from physics and astronomy, to chemistry, biology, and geology, to architecture and naval technology he collaborated or corresponded with scientists as diverse as Christian Huygens, Antony van Leeuwenhoek, Christopher Wren, Robert Boyle, and Isaac Newton. Among other accomplishments, he invented the universal joint, the iris diaphragm, and an early prototype of the respirator invented the anchor escapement and the balance spring, which made more accurate clocks possible served as Chief Surveyor and helped rebuild London after the Great Fire of 1666 worked out the correct theory of combustion devised an equation describing elasticity that is still used today ("Hooke's Law") assisted Robert Boyle in studying the physics of gases invented or improved meteorological instruments such as the barometer, anemometer, and hygrometer and so on. He was the type of scientist that was then called a virtuoso -- able to contribute findings of major importance in any field of science. It is not surprising that he made important contributions to biology and to paleontology.

Relatively little is known about Robert Hooke's life. He was born on July 18, 1635, at Freshwater, on the Isle of Wight, the son of a churchman. He was apparently largely educated at home by his father, although he also served an apprenticeship to an artist. He was able to enter Westminster School at the age of thirteen, and from there went to Oxford, where some of the best scientists in England were working at the time. Hooke impressed them with his skills at designing experiments and building equipment, and soon became an assistant to the chemist Robert Boyle. In 1662 Hooke was named Curator of Experiments of the newly formed Royal Society of London -- meaning that he was responsible for demonstrating new experiments at the Society's weekly meetings. He later became Gresham Professor of Geometry at Gresham College, London, where he had a set of rooms and where he lived for the rest of his life. His health deteriorated over the last decade of his life, although one of his biographers wrote that "He was of an active, restless, indefatigable Genius even almost to the last." He died in London on March 3, 1703.

Hooke's reputation in the history of biology largely rests on his book Micrographia, published in 1665. Hooke devised the compound microscope and illumination system shown above, one of the best such microscopes of his time, and used it in his demonstrations at the Royal Society's meetings. With it he observed organisms as diverse as insects, sponges, bryozoans, foraminifera, and bird feathers. Micrographia was an accurate and detailed record of his observations, illustrated with magnificent drawings, such as the flea shown below, which Hooke described as "adorn'd with a curiously polish'd suite of sable Armour, neatly jointed. . ." It was a best-seller of its day. Some readers ridiculed Hooke for paying attention to such trifling pursuits: a satirist of the time poked fun at him as "a Sot, that has spent 2000 £ in Microscopes, to find out the nature of Eels in Vinegar, Mites in Cheese, and the Blue of Plums which he has subtly found out to be living creatures." More complimentary was the reaction of the diarist and government official Samuel Pepys, who stayed up till 2:00 AM one night reading Micrographia, which he called "the most ingenious book that I ever read in my life."

P erhaps his most famous microscopical observation was his study of thin slices of cork, depicted above right. In "Observation XVIII" of the Micrographia, he wrote:

Hooke had discovered plant cells -- more precisely, what Hooke saw were the cell walls in cork tissue. In fact, it was Hooke who coined the term "cells": the boxlike cells of cork reminded him of the cells of a monastery. Hooke also reported seeing similar structures in wood and in other plants. In 1678, after Leeuwenhoek had written to the Royal Society with a report of discovering "little animals" -- bacteria and protozoa -- Hooke was asked by the Society to confirm Leeuwenhoek's findings. He successfully did so, thus paving the way for the wide acceptance of Leeuwenhoek's discoveries. Hooke noted that Leeuwenhoek's simple microscopes gave clearer images than his compound microscope, but found simple microscopes difficult to use: he called them "offensive to my eye" and complained that they "much strained and weakened the sight."

Hooke was also a keen observer of fossils and geology. While some fossils closely resemble living animals or plants, others do not -- because of their mode of preservation, because they are extinct, or because they represent living taxa which are undiscovered or poorly known. In the seventeenth century, a number of hypotheses had been proposed for the origin of fossils. One widely accepted theory, going back to Aristotle, stated that fossils were formed and grew within the Earth. A shaping force, or "extraordinary Plastick virtue," could thus create to stones that looked like living beings but were not. Hooke's contemporary, the naturalist and shell collector Martin Lister wrote in 1678 that "our English Quarry-shells were not cast in any Animal mold, whose species or race is yet to be found in being at this day." We would now interpret these fossils as belonging to extinct taxa, but extinction was not widely accepted at the time, and Lister concluded: "I am apt to think, there is no such matter, as Petrifying of Shells in the business. . . but that these Cockle-like shells ever were, as they are at present, lapides sui generis [stones of their own kind], and never any part of an Animal."

Hooke examined fossils with a microscope -- the first person to do so -- and noted close similarities between the structures of petrified wood and fossil shells on the one hand, and living wood and living mollusc shells on the other. In Micrographia he compared a piece of petrified wood with a piece of rotten oak wood, and concluded that

Hooke's Discourse of Earthquakes, published two years after his death, shows that his geological reasoning had gone even further. Following in the footsteps of Leonardo da Vinci, Hooke explained the presence of fossil shells on mountains and in inland regions: "Most of those Inland Places. . . are, or have been heretofore under the Water. . . the Waters have been forc'd away from the Parts formerly cover'd, and many of those surfaces are now raised above the level of the Water's Surface many scores of Fathoms. It seems not improbable, that the tops of the highest and most considerable Mountains in the World have been under Water, and that they themselves most probably seem to have been the Effects of some very great Earthquake." Hooke continued to study fossils and compare them with living organisms -- the illustration above shows the coiled shells of three living cephalopods, Nautilus, Argonauta, and Spirula, compared with a fossil ammonite (upper right). He concluded that many fossils represented organisms that no longer existed on Earth: "There have been many other Species of Creatures in former Ages, of which we can find none at present and that 'tis not unlikely also but that there may be divers new kinds now, which have not been from the beginning."

Hooke had grasped the cardinal principle of paleontology -- that fossils are not "sports of Nature," but remains of once-living organisms that can be used to help us understand the history of life. Hooke realized, two and a half centuries before Darwin, that the fossil record documents changes among the organisms on the planet, and that species have both appeared and gone extinct throughout the history of life on Earth. These questions of the nature of fossils and the possibility of extinction would continue to challenge natural scientists, from Edward Lhwyd and John Ray down to Jean-Baptiste Lamarck and Georges Cuvier.

roberthooke.org.uk is an excellent, well-illustrated site on Hooke's life and work, including a number of images from Micrographia.

A brief biography of Hooke, with a listing of his contributions to mathematics, is part of the resources in the history of mathematics maintained at the School of Mathematics of Trinity College, Dublin. A listing of Hooke's biographical data is available from the Galileo Project website. Somewhat more extensive information on Hooke's life and accomplishments is available in this biography, part of the History of Mathematics archive and in the online essay "Seeing Further: The Legacy of Robert Hooke". There is also information about Hooke's contributions to microscopy in the thorough History of the Light Microscope pages.


The Truth About 'The Arc Of The Moral Universe'

Obama so loved the quote that he had it woven into a rug in the Oval Office. It became a favorite of op-ed writers and well-meaning liberals , who used it to remind their audiences of the long road ahead for those committed to progressive politics. Often, Obama used it to temper the hope his presidency inspired, to remind those who had placed their faith in his message of change that it would not be one singular moment, such as the election of the first black president, that would usher in a new and just society.

The dawn of the age of President Donald Trump has restored to that quote some of the meaning lost in Obama’s repeated use. We say it to ourselves now because we need to believe, even as all visible signs of progress are eroded, that the world we seek lies waiting for us, just on the other side of this hellscape. It is not going to show up tomorrow, but knowing that it will show up someday should help fortify us for the fight ahead.

This use of the quotation, though, carries the risk of magical thinking. After all, if the arc of the moral universe will inevitably bend toward justice, then there is no reason for us to work toward that justice, as it’s preordained. If it is only a matter of cosmic influence, if there is no human role, then we are off the hook. This isn’t how King meant it, as evidenced by the work to which he dedicated his own life.

His use of the quote is best understood by considering his source material. “The arc of the moral universe is long, but it bends toward justice” is King’s clever paraphrasing of a portion of a sermon delivered in 1853 by the abolitionist minister Theodore Parker. Born in Lexington, Massachusetts, in 1810, Parker studied at Harvard Divinity School and eventually became an influential transcendentalist and minister in the Unitarian church. In that sermon, Parker said: “I do not pretend to understand the moral universe. The arc is a long one. My eye reaches but little ways. I cannot calculate the curve and complete the figure by experience of sight. I can divine it by conscience. And from what I see I am sure it bends toward justice.”

King’s single sentence is a more tightly wound rhetorical punch, easily deployed for immediate inspiration, but it carries the unintended effect of suggesting that justice is inevitable, so that no matter what we do now, the arc of the moral universe will care for us later. Parker’s sermon, however, forces us into a more active role. He starts by admitting that he does not “understand the moral universe,” which King’s more declarative statement elides. He is less sure of that universe’s contents and of where it may lead, since the “arc is a long one” and his eye “reaches but little ways.” Unable to “calculate the curve and complete the figure by experience of sight” he is left to “divine it by conscience.” This could still be read as somewhat passive. Parker is not reaching out to bend the arc himself rather, he is envisioning what it must look like through his own seemingly enlightened conscience. As an abolitionist and Christian, of course he is sure the arc bends toward justice, or else his work and faith must both be called into question. But his uncertainty about the moral universe is what makes his strong faith a necessity. For Parker, there is no guarantee, that he sees clearly, of the moral universe doing as he wishes. It is only through his own conscience, and thereby his own actions, that justice will be achieved.

King’s quote leaves little room for such uncertainty. The arc will bend toward justice he knows it and wants for us to know it, too. But the longer a quote is divorced from its context, the more easily it is manipulated to unintentional ends. And there have been efforts to ensure this does not happen. In a 2016 interview with CBS , former Attorney General Eric Holder cautioned that “the arc bends toward justice, but it only bends toward justice because people pull it towards justice. It doesn’t happen on its own.”

This, still is, the sort of vague language that offers up the beloved quote as a hollow inspiration. I, too, am guilty of this, of deploying some version of Holder’s comment as an easy applause line that amounts to little more than an empty rhetorical gesture. For as much as progressive movements have come to understand that bending the arc requires work, they have not defined where that work is meant to take us.

“Justice” ― like its rhetorical friends “freedom” and “equality” ― is a word that is allowed to go uninterrogated, as if we are settled on a universal understanding of its meaning. But one woman’s justice might be another woman’s oppression. Americans neither possess any intrinsic notion of what constitutes justice, nor have we adequately adjudicated it through policy or culture. If we had, we’d need none of our current debates about the myriad accusations of sexual abuse and harassment in Hollywood and the allegations they’ve inspired in other industries. We would not be looking at a growing legalized marijuana industry and wondering what to do with the thousands of people behind bars who committed a similar action when the drug was illegal. If we had a real, working conception of “justice,” we would already have answers for these dilemmas. If we were committed to bending the arc toward that widely-accepted notion of justice, we would be acting on those answers by now.

Before we can be active participants in bending the arc of the moral universe, we have to know what we’re bending it toward. How we define “justice” will determine the work that we do to achieve it. And unless we do the work to define “justice,” we never will.

Mychal Denzel Smith is the New York Times bestselling author of Invisible Man, Got the Whole World Watching and a fellow at The Nation Institute.

This piece is part of HuffPost’s brand-new Opinion section. For more information on how to pitch us an idea, go here.


This article was written by Richard Garnett and was published in 1891.

Theodore Edward Hook, novelist and miscellaneous writer, son of James Hook, musical composer, was born in Charlotte Street, Bedford Square, 22 Septe3mber 1788. He was educated at private schools, and subsequently for a short time at Harrow. According to his own account, which may be easily credited, he was principally distinguished at school for mischief, deceptiveness, and an inaptitude for serious application. He had the misfortune to lose an excellent mother at an early age, and his natural failings were fostered by a premature introduction to the theatrical world as author of words for the songs in his father's comic operas. His share in the &lsquoSoldier's Return&rsquo brought him £50 when he was only sixteen and, sometimes in conjunction with his father, sometimes independently, he produced during the next five or six years a number of farces and melodramas. One of the latter, &lsquoTekeli,&rsquo was ridiculed by Byron in &lsquoEnglish Bards and Scotch Reviewers,&rsquo but proved attractive to the public.

Hook's social qualities, however, gained him more celebrity than his dramatic performances his conversation abounded with wit and drollery, his faculty for lyrical and musical improvisation was marvellous, and the exuberance of his animal spirits impelled him to ceaseless practical jokes, sometimes harmless, sometimes heartless, but always clever. The most celebrated was the famous Berners Street hoax, perpetrated in 1809, when the street was blocked up for a whole day by all sorts and conditions of men, from the Duke of Gloucester and the lord mayor to draymen and chimney-sweeps, summoned on various pretexts to besiege the house of a Mrs. Tottenham, who had incurred Hook's displeasure. Upwards of four thousand letters, it is said, had been sent out. Hook's next freak was to take up residence at the university of Oxford, which he left after two terms without having involved himself in any more serious scrape than the risk of banishment, from the excess of complaisance which made him volunteer to sign forty articles should such be the desire of the authorities. Resuming his gay life in town, he became acquainted with the Rev. E. Cannon and other favourites of the Prince of Wales.

It was probably through their and his brother's influence that, at the age of twenty-four, utterly unacquainted as he was with business and arithmetic, he obtained the post of accountant-general and treasurer at Mauritius, where he arrived in October 1813. This apparently miraculous piece of good fortune proved his ruin. When, in 1817, an examination into the state of the treasury was directed by the governor, Hook at first received a full acquittance from every liability but a second investigation, undertaken at the instance of a clerk named Allan, who destroyed himself during the course of it, brought to light a deficiency of sixty-two thousand dollars, of which he could offer no explanation. He was, of course, held responsible, his whole property in the island was confiscated, and he was sent home. Upon his arrival in England the case was investigated by the treasury, who discovered no ground for criminal proceedings, but fixed the civil responsibility upon him for the rest of his life. His remaining property was seized, he was imprisoned from 1823 to 1825, and although, after the final treasury minute, the crown claim for the balance of the debt was allowed to remain dormant during his life, it was revived against his representatives. The fault of this apparently harsh proceeding lay principally with himself. Though for many years receiving an ample income from his pen, he never attempted to discharge any portion of his admitted liability, and had thus forfeited all title to indulgence.

Long before Hook's liberation from confinement he had resorted to his pen for his living. In 1819 and 1820 appeared, with other ephemeral literary work, the clever farce &lsquoExchange no Robbery,&rsquo so unluckily suggestive in title that it had to be brought out under the pseudonym of &lsquoRichard Jones,&rsquo &lsquoThe Arcadian,&rsquo a short-lived magazine, and &lsquoTentamen,&rsquo a satire on Queen Caroline and Alderman Wood, which achieved no little success. If the authorship was known to any, it may have co-operated with the general recommendation of Sir Walter Scott in obtaining for him the editorship of the &lsquoJohn Bull,&rsquo established towards the end of 1820 to counteract the popular enthusiasm for Queen Caroline. Hook's reckless humour and preternatural faculty of improvisation now had full swing, and his powers were never displayed to so much advantage as in this scurrilous, scandalous, but irresistibly facetious, and for a time exceedingly potent journal. No man with a particle of chivalry could have written as Hook did, but no such man could have been equally effective in exposing a pernicious, though generous, popular delusion. He undoubtedly proved himself the prince of lampooners. The exuberance of his impetuous fun sweeps away the studied and polished sarcasms of refined satirists like Moore he hurls ridicule and invective right and left with a Titanic vigour so admirable in itself as a manifestation of energy that we almost forget that after all it is only mud that he is showering. Most of it, however, stuck where it was meant to stick, and his disreputable paper must be named with the &lsquoCraftsman&rsquo and the &lsquoNorth Briton&rsquo among those which have contributed to mould English history. &lsquoIt is impossible to deny,&rsquo says the &lsquoQuarterly Review,&rsquo &lsquothat &ldquoBull&rdquo frightened the Whig aristocracy from countenancing the Court of Brandenburgh House.

The national movement was arrested, and George IV had mainly &ldquoJohn Bull&rdquo to thank for that result.&rsquo It produced another result less satisfactory to the editor when his long-concealed identity leaked out, it became impossible for the treasury to show him the indulgence which would have been represented as the price of his pen, and pique perhaps concurred with carelessness in preventing him from endeavouring to make his defalcations good. He had further encumbered himself with family cares in a very unfortunate manner, having formed an irregular connection, to which he adhered with such strict fidelity that it is surprising he should never have legalised it. Another great mistake was the dissipation of his energies in a number of abortive literary projects, instead of their concentration in his journal, which, after some years of almost unparalleled success, gradually ceased to be a remunerative property. Among these unsuccessful undertakings, however, must not be reckoned his nine volumes of novels published from 1826 to 1829 under the collective title of &lsquoSayings and Doings,&rsquo for which he received little less than £3,000 &lsquoPassion and Principle,&rsquo with its pendant &lsquoCousin William,&rsquo &lsquoGervase Skinner,&rsquo and &lsquoMartha the Gipsy&rsquo are the best known. Hook estimated his own ability as a novelist very accurately. &lsquoGive me,&rsquo he said, &lsquoa story to tell, and I can tell it, but I cannot create.&rsquo This deficiency in invention made him an habitual copyist from the life.

The hero of &lsquoMaxwell&rsquo (1830), his next and most carefully constructed novel, is a close portrait of his friend Cannon, and his later works, &lsquoGilbert Gurney&rsquo and &lsquoGurney Married&rsquo (1836 and 1838), are little else than a gallery of thinly disguised portraits and a string of anecdotes from real life, so excellently told, however, that these slight performances seem likely to survive his more ambitious writings. They appeared in the &lsquoNew Monthly Magazine,&rsquo of which he had become editor in 1836. In the interval he had written (1833) &lsquoThe Parson's Daughter&rsquo and &lsquoLove and Pride,&rsquo and (1832) a life of Sir David Baird, a work apparently quite out of his line, but which satisfied the family and the public. &lsquoJack Brag,&rsquo 1836, is a successful parasite's mockery of an unsuccessful one. He also rewrote the reminiscences of Michael Kelly and commenced a life of Charles Mathews, which was discontinued from differences with the family. His last novel of importance was &lsquoBirths, Marriages, and Deaths,&rsquo 1839 subsequent publications, the dregs of his failing powers, were believed to be only partially from his own hand. During the last six or seven years of his life Hook was steadily sinking in health, in circumstances, and in literary power, and the inner history of his life is truly tragic.

Received into the highest circles, admired, caressed, applauded for his unequalled social talent, he was, as he knew well, regarded merely as a hired jester, whose failure to amuse his patrons would be visited by prompt expulsion from their society. While apparently the soul of gaiety abroad, at home he led the life of the hunted and harassed author while the dissipations of the gay world broke down his health, domestic cares weighed heavily upon his really affectionate disposition and the scenes where he shone and sparkled were darkened by the great shadow of his unredeemed and unredeemable debt. Lockhart has raised the veil in a most powerful passage in the &lsquoQuarterly,&rsquo reinforced by significant extracts from Hook's diary. Portraits of him as he appeared at this time to those who chiefly knew him as Lord Hertford's parasite appear in &lsquoConingsby,&rsquo where he is introduced as &lsquoLucian Gay,&rsquo and in &lsquoVanity Fair,&rsquo where he figures as &lsquoMr. Wagg.&rsquo &lsquoDone up in purse, in mind, and in body,&rsquo as he said himself, he expired at his house at Fulham on 24 August 1841. His effects were seized by the crown as preferential creditor, but his family were provided for by a subscription, in which the names of his aristocratic patrons, the king of Hanover's excepted, were not to be found.

Hook was a better man than would be easily discovered from his writings. &lsquoHe was,&rsquo says Lockhart, &lsquohumane, charitable, generous. There was that about him which made it hard to be often in his society without regarding him with as much of fondness as of admiration.&rsquo His defects were a moral vulgarity, far more offensive than the social vulgarity it ridiculed, and a want of every quality especially characteristic of a high-minded man. In the less exalted sphere of the social affections he was exemplary, and much of his apparent dissipation was forced upon him by the necessity of keeping in society to keep out of gaol. &lsquoHis real tastes,&rsquo says Lockhart, &lsquowere simple enough.&rsquo His unflagging literary industry in the midst of so many hindrances and temptations is highly to his credit. Though he sold his pen, he did not prostitute it the side in support of which his wit and scurrility were enlisted was really his own. His natural powers were extraordinary. &lsquoHe is,&rsquo said Coleridge, &lsquoas true a genius as Dante.&rsquo With regular education and mental discipline he might have done great things his actual reputation is that of a great master in a low style of humour, and the most brilliant improvisatore, whether with the pen or at the piano, that his country has seen.

These materials may be freely used for non-commercial purposes in accordance with applicable statutory allowances and distribution to students.
Re-publication in any form is subject to written permission.


HOOKIPA Pharma Inc. (HOOK)

A look at the shareholders of HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) can tell us which group is most powerful.

Place A Bag On Your Car Mirror When Traveling

Brilliant Car Cleaning Hacks Local Dealers Wish You Didn’t Know

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in June

NEW YORK and VIENNA, Austria, June 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences: SVB Leerink CybeRx Series: Vaccine Forum, June 21 – 22, 2021JMP Securities Life Sciences Conference, June 16 – 17, 2021Fireside Chat: June 17, 10:00am ET Th

Hookipa Pharma's Cancer Immunotherapy Shows T-Cell Response, Interim Efficacy in Pretreated HPV16+ Cancer Settings

Hookipa Pharma Inc (NASDAQ: HOOK) reported positive Phase 1 data from its ongoing Phase 1/2 study evaluating HB-200 to treat advanced Human Papillomavirus 16-positive (HPV16+) cancers. Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. At baseline, all patients had nearly undetectable levels of tumor-specific T cells. Within two weeks of a single dose of HB-200, all patients showed increased tumor-specific CD8+ T cell levels. ​ As of the data cut-off, (1

HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers

Novel arenaviral therapeutic HB-200 generates outstanding tumor antigen-specific CD8+ T cell responses (average of 6 percent and up to 40 percent of T cell pool)To-date, HB-201 monotherapy has shown 18 percent overall response rate and median progression-free survival of 3.45 months in heavily pretreated head and neck cancer patientsClinical data replicate pre-clinical results, showcasing the potential of HOOKIPA’s arenaviral platform to produce multiple potent cancer immunotherapies NEW YORK an

HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO

Data from first-in-human Phase 1 study of arenaviral therapeutics, including first data on HB-201/HB-202 alternating 2-vector therapy and expanded data on HB-201, to be featured as oral presentationEarly dose escalation study will highlight antigen-specific CD8+ T cell data, anti-tumor activity and overall tolerability of HB-201 and HB-201/HB-202 HOOKIPA’s arenaviral platform poised to deliver a new class of potent immunotherapeutics in cancer treatment NEW YORK and VIENNA, Austria, May 20, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first data on HB-201/HB-202 alternating 2-vector therapy and expanded data on HB-201 will be featured as an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021. HB-201 and HB-202, novel arenaviral therapeutics and HOOKIPA’s lead oncology candidates, are being evaluated in an ongoing, first-in-human Phase 1/2 clinical trial (NCT04180215) for the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers. The oral presentation will highlight safety, tolerability, immunogenicity and preliminary anti-tumor activity data from about 40 evaluable patients as of March 31. “We’re thrilled that our novel arenaviral immunotherapeutics for HPV16+ cancers, HB-201 and HB-202, are being featured at ASCO. We believe our selection as an oral presentation speaks to the strength of the data and the potential of our arenaviral therapeutics to redefine success in cancer treatment,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “Following the preliminary HB-201 data shared in December and our translational data presentation at AACR, we’re excited to share expanded data from more patients and additional doses, including first results on HB-201/HB-202 alternating 2-vector therapy, as well as detailed safety, tolerability, translational data and preliminary anti-tumor activity results. We believe these data are very encouraging for such an early-stage program.” The abstract, outlined below, is available on the ASCO website: First report of the safety/tolerability and preliminary anti-tumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers Abstract # 2502, oral presentationMonday, June 7, 3:00 - 6:00pm EDTPresenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center Investor EventAt the conclusion of the planned ASCO conference events on June 7, 2021, HOOKIPA will host a live webcast event “Advancing Novel Immunotherapies: HOOKIPA ASCO Data Review” at 6:30 p.m. EDT. Joern Aldag, Chief Executive Officer, and Igor Matushansky, Chief Medical Officer, will provide an overview of the ASCO oral data and future plans for HOOKIPA’s oncology program. Dmitriy Zamarin, M.D., Ph.D., Translational Research Director in Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center and co-investigator in this study, will also offer commentary on the significance and implications of the translational findings. The webcast and the presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. To participate in a live Q&A at the end of the prepared remarks, please register here. An archived replay will be accessible for 30 days following the event. About HB-201/HB-202HB-201 and HB-202 are HOOKIPA’s lead oncology candidates engineered with the company’s proprietary replicating arenaviral vector platform. Each single-vector compound uses a different arenavirus backbone (LCMV for HB-201 and PICV for HB-202), while expressing the same antigen, an E7E6 fusion protein derived from HPV16. In pre-clinical studies, alternating administration of HB-201 and HB-202 resulted in a ten-fold increase in immune response and better disease control than either compound alone. About the trialThis Phase 1/2 clinical trial is an open-label trial exploring different dose levels and dosing schedules in individuals with treatment-refractory HPV16+ cancers who progressed on standard of care, including check point inhibitors. The primary endpoint of the Phase 1 is a recommended Phase 2 dose based on safety and tolerability. Secondary endpoints include anti-tumor activity as defined by RECIST 1.1 and immunogenicity. The trial is evaluating HB-201 as a single-vector monotherapy, as an alternating two-vector therapy with HB-202, and in combination with a PD-1 inhibitor. Participants receive HB-201/HB-202 intravenously or, for patients with an accessible lesion, the first dose can be delivered via intratumoral injection followed by intravenous dosing. Dosing every three weeks and every two weeks is being explored, as well as different dose levels. About Human PapillomavirusHuman Papillomavirus, or HPV, is estimated to cause about 5 percent of the worldwide burden of cancers. This includes approximately 99 percent of cases in cervical, up to 60 percent of head and neck, 70 percent of vaginal and 88 percent of anal cancers. The majority of these cancers are caused by the HPV serotype 16. Most infections with HPV are cleared from the body with no lasting consequences. However, in some cases, HPV DNA becomes integrated into chromosomal DNA. When host cells take up this DNA, they express the HPV E6 and E7 proteins. This uptake can potentially lead to cancer since expression of these proteins leads to alterations in cell cycle control, which in turn predisposes these cells to become cancerous.About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies that mobilize and amplify targeted T cells and antibodies, the body’s natural infection killers, to fight or prevent serious disease. HOOKIPA is developing a broad pipeline of potential first-in-class arenaviral immunotherapies in oncology and infectious disease. We are leveraging our proprietary, flexible platform to engineer arenaviral therapeutics that induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies to a broad range of self and non-self antigens, including viral antigens, tumor-associated antigens and neoantigens. Our immunotherapies are designed to use either non-replicating or replicating viral vectors based on the target disease, with the potential to induce CD8+ T cell response levels previously not achieved by other immunotherapy approaches. HOOKIPA’s pipeline include three ongoing clinical trials in Human Papilloma Virus 16-positive cancers and Cytomegalovirus, as well as preclinical research in prostate cancer, HIV and Hepatitis B. The latter two are in collaboration with Gilead Sciences, Inc. Find out more about HOOKIPA online at www.hookipapharma.com. Forward Looking Statements Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results for HB-101 and other programs, and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA’s ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s annual report on Form 10-Q for the financial year ended March 31, 2021 which is available on the Security and Exchange Commission’s website at www.sec.gov and HOOKIPA’s website at www.hookipapharma.com. Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website. For further information, please contact: MediaNina WaibelSenior Director - [email protected] InvestorsMatt Beck Executive Director - Investor [email protected] Media enquiriesInstinctif [email protected] +44 (0)20 7457 2020

How to fall in love with a new language?

We Tested This App To See If You Could Learn A Language In 7 Days.

HOOKIPA Pharma Inc. (HOOK) Soars 7.9%: Is Further Upside Left in the Stock?

HOOKIPA Pharma Inc. (HOOK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Tops Revenue Estimates

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 0.00% and 38.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent Highlights

Oncology programs advance with preliminary Phase 1 immunogenicity data showing robust antigen-specific CD8+ T cell response after one dose of HB-201 or HB-202 clinical results consistent with those observed in pre-clinical studiesHOOKIPA on track to report additional HB-201 and HB-202 clinical data on T cell response and preliminary antitumor activity at ASCO and other upcoming conferences NEW YORK and VIENNA, Austria, May 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2021. “We had a strong start to the year as we drive our pipeline forward to deliver a new class of arenavirus-based immunotherapeutics. As we shared at AACR, one initial dose of our lead oncology candidates, HB-201 or HB-202, each induced a robust increase in antigen-specific T cells, including an increase of up to 8% of antigen-specific circulating CD8+ T cells, in people with advanced Human Papillomavirus 16-positive (HPV16+) cancers,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “We believe these data are impressive, and they are consistent with the pre-clinical data published in Cell Reports Medicine in March. Both data sets highlight the potential of our engineered arenavirus platform to redefine success in cancer immunotherapy. As our clinical programs progress, we’re excited about the oral abstract presentation at ASCO (#2502) and other future data presentations at upcoming conferences.” Program Highlights In April 2021, HOOKIPA announced positive preliminary Phase 1 immunogenicity data for its lead oncology candidates, HB-201 and HB-202, for the treatment of advanced HPV16+ cancers, reinforcing the promising anti-tumor activity reported from the Phase 1/2 clinical trial in December 2020. The preliminary immunogenicity data demonstrated a robust increase in HPV16+-specific T cells, including an increase of up to 8% of antigen-specific circulating CD8+ T cells, after one dose of HB-201 or HB-202. Early HB-201 monotherapy data also highlighted immune system activation of increasing interferon-gamma and other immune stimulatory cytokines with a single dose. The data were presented at a late-breaker poster session at the virtual American Association for Cancer Research (AACR) Annual Meeting. In March, Cell Reports Medicine published pre-clinical data on HOOKIPA’s arenaviral therapeutics. The peer-reviewed article showed that intravenous HB-201 administration induced single digit percentage of antigen-specific CD8+ T cells, while alternating administration of HB-201 and HB-202 induced a potent CD8+ T cell response, exceeded 50% of the circulating T cell pool. The two-vector cancer therapeutic approach also resulted in tumor cures and long-term immunity in a pre-clinical setting. HOOKIPA’s prophylactic Cytomegalovirus, or CMV, vaccine candidate, HB-101, continued to enroll patients awaiting kidney transplantation in a Phase 2 clinical trial. We expect to conclude trial enrollment in mid-2021 and to report additional safety, immunogenicity, and efficacy data from evaluable patients in the second half of 2021. Upcoming Milestones Oral abstract presentation at ASCO (#2502 at 3:00pm EDT on June 7): First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancersInitial HB-201/HB-202 Phase 1/2 efficacy data in HPV16+ cancers in mid-2021Additional HB-101 CMV Phase 2 efficacy data in H2 2021Advancing our HB-300 to IND for the treatment of metastatic prostate cancerHBV and HIV collaboration with Gilead Sciences advancing towards clinical studies First Quarter 2021 Financial Results Cash Position: HOOKIPA’s cash, cash equivalents and restricted cash as of March 31, 2021 was $128.1 million compared to $143.2 million as of December 31, 2020. The decrease was primarily attributable to cash used in operating activities. Revenue was $5.3 million for the three months ended March 31, 2021, and $3.7 million for the three months ended March 31, 2020. The increase was primarily due to higher cost reimbursements received under the Collaboration Agreement with Gilead and the recognition of cost reimbursements initially recognized as deferred revenue. Research and Development Expenses: HOOKIPA’s research and development expenses were $20.2 million for the three months ended March 31, 2021, compared to $11.5 million for the three months ended March 31, 2020. The primary drivers of the increase in direct research expenses were an increase in clinical trial expenses of $1.5 million and an increase in manufacturing and quality control expenses of $4.6 million. The increase was mainly due to the progress in our HB-201 and HB-202 clinical trial, the increased patient recruitment in our HB-201 and HB-202 clinical trial, monitoring and testing activities and manufacturing and quality control work in preparation of a further extension of the trial. Manufacturing and quality control expenses were also driven by the progress towards clinical development in our Gilead partnered programs. This increase in HB-201/HB-202 and Gilead related direct expenses was partially offset by a decrease in direct costs related to our HB-101 program due to slower patient recruitment as a result of the COVID pandemic. The increase in internal research and development expenses was mainly due to an increase of personnel-related research and development expenses, resulting primarily from a higher headcount, while stock-based compensation expenses included in personnel-related research and development expenses decreased. In addition, an increase in facility related costs and an increase in other internal costs contributed to the overall increase in internal research and development expenses. General and Administrative Expenses: General and administrative expenses for the three months ended March 31, 2021 were $4.3 million, compared to $4.6 million for the three months ended March 31, 2020. The decrease was primarily due to a decrease in personnel-related expenses, partially offset by an increase in professional and consulting fees. The decrease in personnel-related expenses resulted from decreased stock compensation expenses, partially offset by increased salaries and a growth in headcount in our general and administrative functions. Net Loss: HOOKIPA’s net loss was $17.2 million for the three months ended March 31, 2021 compared to a net loss of $10.9 million for the three months ended March 31, 2020. This increase was due to an increase in research and development expenses, partially offset by an increase in revenues from collaboration and licensing, a decrease in general and administrative expenses, and an increase in grant income. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial. HOOKIPA’s non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic hepatitis B infections. Find out more about HOOKIPA online at www.hookipapharma.com. HOOKIPA Forward Looking StatementsCertain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results for HB-101 and other programs, and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA’s ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s quarterly report on Form 10-Q for the quarter ended March 31, 2021 which is available on the Security and Exchange Commission’s website at www.sec.gov and HOOKIPA’s website at www.hookipapharma.com. Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website. HOOKIPA Pharma Inc.Consolidated Statements of Operations (Unaudited)(In thousands, except share and per share data) Three months ended March 31, 2021 2020Revenue from collaboration and licensing $5,301 $3,696 Operating expenses: Research and development (20,164) (11,526)General and administrative (4,309) (4,629)Total operating expenses (24,473) (16,155)Loss from operations (19,172) (12,459)Total interest, other income and taxes, net 1,934 1,533 Net loss $(17,238) $(10,926)Net loss per share — basic and diluted (0.53) (0.43) Condensed Balance Sheets (Unaudited)(In thousands) As of As of March 31, December 31, 2021 2020Cash, cash equivalents and restricted cash $128,145 $143,177Total assets 169,941 187,817Total liabilities 29,886 31,694Total stockholders’ equity 140,055 156,123 For further information, please contact: MediaInvestorsNina WaibelMatt BeckSenior Director - CommunicationsExecutive Director - Investor [email protected]@hookipapharma.com Media enquiries Instinctif Partners [email protected] +44 (0)20 7457 2020

Is a Surprise Coming for HOOKIPA (HOOK) This Earnings Season?

HOOKIPA (HOOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Mad Neighbor Got Karma When The Couple Bought.

After so much drama and many police visits, she got the upper hand. Who would’ve thought that a small piece of paper has such power?

HOOKIPA Pharma Inc. (HOOK) Expected to Beat Earnings Estimates: Should You Buy?

HOOKIPA Pharma Inc. (HOOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HOOKIPA Pharma to Report First Quarter 2021 Financial Results on Wednesday, May 12, 2021

NEW YORK and VIENNA, Austria, May 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2021 financial results before the market opens on Wednesday, May 12, 2021. The Company will not be conducting a conference call in conjunction with this earnings release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial. HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections. Find out more about HOOKIPA online at www.hookipapharma.com. For further information, please contact: MediaInvestorsNina WaibelMatt BeckSenior Director - CommunicationsExecutive Director - Investor [email protected]@hookipapharma.com

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

NEW YORK and VIENNA, Austria, April 29, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences: 7th Annual Truist Securities Life Sciences Summit, May 4 – 5, 2021Fireside Chat: May 4, 1:50pm ET Bank of America 2021 Health Care Conference, May 10 – 13, 2021Presentation: May 13, 1:15pm ET Morgan Stanley Virtual Asia Healthcare Conference, May 13 - 14, 2021RBC Capital Markets Global Healthcare Conference, May 18 - 20, 2021Fireside Chat: May 18, 9:45am ET The live audio webcasts of the fireside chats and presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial. HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections. Find out more about HOOKIPA online at www.hookipapharma.com. For further information, please contact: MediaInvestorsNina WaibelMatt BeckSenior Director - CommunicationsExecutive Director - Investor [email protected]@hookipapharma.com

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the.

HOOKIPA Pharma to Present at Kempen Life Science Conference

NEW YORK and VIENNA, Austria, April 14, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and host 1:1 meetings at the virtual Kempen Life Science Conference, taking place April 21, 2021. Additional information will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial. HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections. Find out more about HOOKIPA online at www.hookipapharma.com. For further information, please contact: Media InvestorsNina Waibel Matt BeckSenior Director - Communications Executive Director - Investor [email protected] [email protected]

HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers

Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202Early data on HB-201 monotherapy show an increase in interferon-gamma and other immune stimulatory cytokines after a single dose, highlighting immune system activationLate-breaker data at AACR Annual Meeting reinforce promising anti-tumor activity reported in 2020 and underscore the potential of HOOKIPA’s novel arenavirus platform to deliver transformational cancer therapies NEW YORK and VIENNA, Austria, April 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive preliminary Phase 1 immunogenicity data for its lead oncology candidates, HB-201 and HB-202, to treat Human Papillomavirus 16-positive (HPV16+) cancers. The results are from an ongoing Phase 1/2 study (NCT04180215) currently investigating HB-201 as a single-vector therapy and HB-201 and HB-202 as an alternating two-vector therapy for the treatment of advanced metastatic HPV16+ cancers. The data were presented today at a late-breaker poster session at the virtual American Association for Cancer Research Annual Meeting. “We’re excited to see the quantity and quality of a targeted immune response, particularly the directly measured increase in HPV16+-specific CD8+ T cells, generated by a single dose of our lead oncology candidates, HB-201 or HB-202. As we are still exploring optimal dosing, these early responses are particularly encouraging,” said Joern Aldag, Chief Executive Officer of HOOKIPA. “We believe our novel arenavirus platform has the potential to introduce a new class of immunotherapeutics that could considerably advance how physicians care for people with HPV16+ cancers. Building on the early clinical results reported on HB-201 in December, we look forward to additional data read-outs from our first clinical oncology program in the coming months.” Preliminary data showed a strong antigen-specific T cell response after one dose of HB-201 or HB-202, based on direct Enzyme-Linked ImmunoSpot (ELISpot) T cell analysis. (ELISpot is used to quantify antigen-specific T cells in the blood.) All 5 patients who received a single dose of HB-201 or HB-202 had a strong induction of T cells specific to HPV16+ cancer 2 weeks after administration. An up to 250-fold increase in antigen-specific T cells was observed 2 weeks after a single dose of HB-201 in 4 patients. One patient who received a single dose of HB-202 showed a 150-fold increase in antigen-specific T cells 2 weeks after administration. Importantly, the results are based on direct ELISpot without ex vivo expansion of T cells, underscoring the magnitude of T cell response generated by one dose of HB-201 or HB-202. (Ex vivo expansion is often used to amplify responses so that they are more easily measured.) The data are derived from dose level 2 of ongoing dose escalation, and the recommended Phase 2 doses for HB-201 and HB-202 have not been reached. In addition, analysis of the antigen-specific T cell response showed an increase in CD8+ T cells specific to HPV16+ cancer after a single dose of HB-201 (baseline 0% to 2.8% two weeks later) and HB-202 (baseline 0% to 8.1% two weeks later). These data were assessed using intracellular cytokine staining (ICS) followed by flow cytometry, which differentiates antigen-specific CD8+ T cells (cytotoxic/killer T cells) from antigen-specific CD4+ T cells (helper T cells). Of note, the HPV16+ cancer patients included in this analysis had negligible levels of antigen-specific CD8+ T cells prior to treatment with HB-201 or HB-202. Other preliminary immunogenicity data highlight immune system activation following a single dose of HB-201. Blood samples from 12 patients were assessed across 13 timepoints for levels of 30 different cytokines and chemokines, which play critical roles in activating an immune response. At the time of data cut-off, baseline and day 4 samples were available for 9 of the 12 patients. The analysis showed that, 4 days after a single dose of HB-201, interferon-gamma levels increased in 90% of patients, and an increase in other immune stimulatory cytokines and chemokines was observed. These data comprise an early sign of natural killer (NK) cell and/or T cell activation by HB-201. “Treatment options are limited for people with metastatic HPV16+ cancers, and the likelihood for long-term survival is low,” said Dmitriy Zamarin, MD, PhD, Translational Research Director in Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center and co-investigator in this study. “We don’t often see this robust and high-quality immune response, particularly in antigen-specific CD8+ T cells, from a single dose and without any combination therapy. I’m excited to see how these early immunogenicity data may translate to clinical outcomes in the future.” These preliminary immunogenicity data reinforce the promising anti-tumor activity reported from this trial in December 2020 and are consistent with recently published preclinical data, which showed that intravenous HB-201 administration induced single digit percentage of antigen-specific CD8+ T cells, while alternating administration of HB-201 and HB-202 induced a potent CD8+ T cell response, exceeding 50% of the circulating T cell pool. As the HB-201/HB-202 clinical trial is ongoing, HOOKIPA expects to present additional translational and clinical data at upcoming medical conferences in 2021. The company anticipates these data to further inform the HPV program, as well as other earlier stage programs in its oncology pipeline, including therapeutics for prostate cancer, as it seeks to deliver transformational therapies through induction of antigen-specific CD8+ T cells. The poster and audio review are available at https://ir.hookipapharma.com/events/event-details/aacr-annual-meeting-2021. About HB-201/HB-202HB-201 and HB-202 are HOOKIPA’s lead oncology candidates engineered with the company’s proprietary replicating arenaviral vector platform. Each single-vector compound uses a different arenavirus backbone (LCMV for HB-201 and PICV for HB-202), while expressing the same antigen, an E7E6 fusion protein derived from HPV16. In pre-clinical studies, alternating administration of HB-201 and HB-202 resulted in a ten-fold increase in immune response and better disease control than either compound alone. About the trialThis Phase 1/2 clinical trial is an open-label trial exploring different dose levels and dosing schedules in individuals with treatment-refractory HPV16+ cancers. The primary endpoint of the Phase 1 is a recommended Phase 2 dose based on safety and tolerability. Secondary endpoints include anti-tumor activity as defined by RECIST 1.1 and immunogenicity. The trial is evaluating HB-201 as a single-vector monotherapy, as an alternating two-vector therapy with HB-202, and in combination with a PD-1 inhibitor. Participants receive HB-201/HB-202 intravenously or, for patients with an accessible lesion, the first dose can be delivered via intratumoral injection followed by intravenous dosing. Dosing every three weeks and every two weeks is being explored, as well as different dose levels. HOOKIPA expects to share interim clinical data on the HB-201/202 therapy in mid-2021. About Human PapillomavirusHuman Papillomavirus, or HPV, is estimated to cause about 5 percent of the worldwide burden of cancers. This includes approximately 99 percent of cases in cervical, up to 60 percent of head and neck, 70 percent of vaginal and 88 percent of anal cancers. The majority of these cancers are caused by the HPV serotype 16. Most infections with HPV are cleared from the body with no lasting consequences. However, in some cases, HPV DNA becomes integrated into chromosomal DNA. When host cells take up this DNA, they express the HPV E6 and E7 proteins. This uptake can potentially lead to cancer since expression of these proteins leads to alterations in cell cycle control, which in turn predisposes these cells to become cancerous.About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial. HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections. Find out more about HOOKIPA online at www.hookipapharma.com. Forward Looking StatementsCertain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results for HB-101 and other programs, and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA’s ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s annual report on Form 10-K for the financial year ended December 31, 2020 which is available on the Security and Exchange Commission’s website at www.sec.gov and HOOKIPA’s website at www.hookipapharma.com. Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website. For further information, please contact: Media InvestorsNina Waibel Matt BeckSenior Director - Communications Executive Director - Investor [email protected] [email protected] Media enquiries Instinctif Partners [email protected] +44 (0)20 7457 2020

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 17.86% and 0.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma: Q4 Earnings Insights

Shares of HOOKIPA Pharma (NASDAQ:HOOK) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 15.00% over the past year to (.46), which beat the estimate of (.58). Revenue of $5,163,000 higher by 42.70% from the same period last year, which beat the estimate of $4,260,000. Outlook HOOKIPA Pharma hasn't issued any earnings guidance for the time being. HOOKIPA Pharma hasn't issued any revenue guidance for the time being. Details Of The Call Date: Mar 18, 2021 View more earnings on HOOK Time: 08:30 AM ET Webcast URL: https://edge.media-server.com/mmc/p/ah8vsuip Technicals Company's 52-week high was at $13.68 Company's 52-week low was at $6.00 Price action over last quarter: Up 13.55% Company Description HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 18, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Outlook

Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidatesFollow-on offering strengthened cash basis with $143 million available at year-end to support progression of Human Papillomavirus 16-positive (HPV16+) cancer and Cytomegalovirus (CMV) programs and pipeline expansion HOOKIPA on track to report additional clinical data on efficacy and T cell response in 2021 for HB-201 and HB-202 NEW YORK and VIENNA, Austria, March 18, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2020. “Despite the global pandemic, 2020 was a break-out year for HOOKIPA, a testament to the strength of our novel scientific platform and our dedicated team. We reported compelling, early clinical data with both our replicating and non-replicating technologies in oncology and infectious diseases, respectively, and advanced the HBV and HIV cures towards the clinic in our strategic collaboration with Gilead Sciences. With the appointment of Jean-Charles Soria, M.D., Ph.D., we added a globally recognized oncology expert to our board to help guide our clinical development progress,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “Our strong year-end cash balance of $143 million positions us well to advance our CMV and HPV16+ cancer programs and to expand our pipeline. Given the strength of the interim data reported in 2020, we are excited about the further potential of our platform and additional read-outs this year, particularly from our HB-201/HB-202 two-vector alternating immunotherapy, which has the potential to deliver even greater immune response than HB-201 alone.” R&D Pipeline Update and Clinical Progress Oncology Portfolio (HB-201 and HB-202) Clinical proof of concept achieved with HB-201. In December, interim Phase 1 data on HB-201 for the treatment of advanced HPV16+ cancers showed promising anti-tumor activity and favorable tolerability as a monotherapy, i.e. without any additional combination product. Data demonstrated responses and stable disease in head and neck cancer patients who failed prior standard of care therapy, platinum therapy, PD(L)1 inhibitor, or both. By targeting an antigen common to HPV16+, HB-201 has the potential to be a tumor-agnostic therapy for all HPV16+ cancers. These early-stage data establish proof of concept for HOOKIPA’s replicating single-vector immunotherapy in oncology. Dose escalation and dose frequency continue to be evaluated in the ongoing Phase 1/2 trial, with the next data read-out anticipated by mid-2021. HPV is estimated to cause 5% of the worldwide cancer burden, the majority of which is HPV16+.First patient dosed with HB-202. HOOKIPA expanded its Phase 1/2 HB-201 clinical trial to include evaluation of HB-201/HB-202, an alternating two-vector therapy. Following clearance of the IND by the Food and Drug Administration in June 2020, the first patient was dosed with HB-202 in October 2020. Preclinical data show that adding an additional arenaviral vector to achieve alternating two-vector therapy can enhance the immune response. Initial data read-out is anticipated by mid-2021.OncoImmunology published HB-201 pre-clinical data demonstrating high immunogenicity. In September, pre-clinical data on HB-201 in HPV16+ models were published in OncoImmunology. Specifically, intravenous administration of HB-201 elicited a robust expansion of antigen-specific CD8+ T cell responses. In the HPV16+ tumor model, HB-201 showed significantly delayed tumor growth or complete tumor clearance with prolonged survival. Pre-clinical data highlighting the potential of alternating two-vector cancer therapeutics published in Cell Reports Medicine. The March 2021 issue of Cell Reports Medicine featured pre-clinical data showing that alternating, intravenous administration of two replicating arenaviral vectors induced tumor-specific responses exceeding 50% of circulating CD8 T cells. In addition, the two-vector approach resulted in tumor cures and long-term immunity in a pre-clinical setting. HOOKIPA is currently evaluating the alternating two-vector therapy in its ongoing HB-201/HB-202 clinical trial, with initial data read-out anticipated by mid-2021. Infectious Disease Portfolio (HB-101) Clinical proof of concept achieved with HB-101. In November, interim Phase 2 data were released for patients who received a three-dose CMV vaccination with HB-101 prior to a kidney organ transplantation. These interim results showed a reduction in CMV viremia, reduction in antiviral use, and no CMV disease in the CMV-negative kidney transplant recipients as compared to placebo. Strong CMV-neutralizing antibody responses and a favorable tolerability profile were also observed. HOOKIPA believes that these interim data establish proof of concept for HB-101, a potential first-in-class vaccine candidate, which uses HOOKIPA’s non-replicating technology. HOOKIPA expects to conclude enrollment of the ongoing Phase 2 trial in mid-2021 and to report additional data in the second half of 2021. Scientific validation with Phase 1 HB-101 data publication in The Journal of Infectious Diseases. In April, Phase 1 safety and immunogenicity data on HB-101 were published in The Journal of Infectious Diseases. The trial concluded that the CMV vaccine candidate was well-tolerated and induced strong neutralizing antibody and T cell immune responses against CMV in healthy adult volunteers. Strategic Collaborations Gilead Sciences collaboration for Hepatitis B Virus and HIV therapeutic vaccines advances. HOOKIPA’s collaboration with Gilead aims to develop immunotherapy candidates for functional cures of Hepatitis B Virus and HIV in combination therapies. Significant progress was made in the collaboration during 2020. In the fourth quarter, another pre-clinical milestone was triggered in the HIV program, bringing the total revenue recorded from the Gilead collaboration in 2020 to $19.6 million. Gilead agreed to reserve manufacturing capacity and expanded resources to support future clinical trials. Corporate Highlights Balance sheet strengthened with $80.9m financing. Following the positive data read-outs in both the oncology and infectious disease programs, HOOKIPA completed a successful follow-on offering to close the year with a cash balance of $143.2 million. Funding will support advancement of the HPV16+ and CMV programs and an expansion of the overall pipeline.Board of Directors adds expertise in late-stage oncology clinical development. In October, HOOKIPA welcomed Professor Jean-Charles Soria, M.D., Ph.D., Director General of the Gustave Roussy Cancer Center in Paris, as a Board Director. Dr. Soria is a globally recognized physician-scientist who brings deep oncology, immunotherapy and clinical development expertise to the Board.Strong management through COVID-19 uncertainty. Despite the challenges of the pandemic, HOOKIPA’s team was able to continue to deliver effectively on our corporate goals. HOOKIPA quickly pivoted early on to maintain its laboratory and manufacturing operations with appropriate safety precautions, while other employees were able to maintain productivity via remote work. HOOKIPA continues to monitor the impact of the ongoing pandemic on its overall operations. Upcoming Milestones Translational data from the HB-201 program in Q2 2021Additional HB-201 and initial HB-201/HB-202 Phase 1/2 efficacy data in HPV16+ cancers in mid-2021Additional HB-101 CMV Phase 2 efficacy data in H2 2021Advancing HB-300 towards IND for the treatment of metastatic prostate cancerHBV and HIV collaboration with Gilead Sciences advancing towards clinical studies Fourth Quarter and Full Year 2020 Financial Results Cash Position: HOOKIPA’s cash, cash equivalents and restricted cash as of December 31, 2020 was $143.2 million compared to $113.6 million as of December 31, 2019. The increase was primarily attributable to $75.0 million in net proceeds from the issuance of common stock and convertible preferred stock in a follow-on financing in December 2020, offset by cash used in operating activities. Revenue was $5.2 million for the three months ended December 31, 2020, and $19.6 million for the year ended December 31, 2020 compared to $3.6 million for the three months ended December 31, 2019 and $11.9 million for the year ended December 31, 2019. The increase was primarily due to higher cost reimbursements received under the collaboration agreement with Gilead and the partial recognition of a milestone payment we received from Gilead in February 2020. Research and Development Expenses: HOOKIPA’s research and development expenses were $15.7 million for the three months ended December 31, 2020, and $54.8 million for the year ended December 31, 2020 compared to $11.2 million for the three months ended December 31, 2019, and $46.3 million for the year ended December 31, 2019. The primary driver of the increase in research and development expenses by $8.5 million compared to 2019 was an increase in internal research and development expenses, partially offset by a decrease in direct research and development expenses. Internal research and development expenses increased primarily due to higher personnel expenses, including stock based compensation and an increase in facility related expenses. The decrease in direct expenses was primarily due to a decrease in research and development service expenses, along with a decrease in manufacturing and quality control expenses and a decrease of other direct research and development expenses, partially offset by an increase in clinical trial expenses and an increase in laboratory expenses. General and Administrative Expenses: General and administrative expenses amounted to $4.7 million for the three months ended December 31, 2020 and $18.1 million for the for the year ended December 31, 2020 compared to $5.7 million for the three months ended December 31, 2019, and $16.7 million for the year ended December 31, 2019. The increase was mainly due to the growth in personnel related expenses as well as costs associated with ongoing business activities and costs to operate as a public company, partially offset by a decrease in professional and consulting fees. Net Loss: HOOKIPA’s net loss was $12.5 million for the three months ended December 31, 2020 and $44.1 million for the year ended December 31, 2020 compared to a net loss of $10.2 million for the three months ended December 31, 2019 and $43.0 million for the year ended December 31, 2019. This increase was due to an increase in research and development expenses, mainly driven by the progression of HOOKIPA’s oncology programs, and an increase in general and administrative expenses to operate as a public company. Conference call: HOOKIPA will host a conference call and live webcast at 8:30 am EDT to discuss its financial results. Please register here to access the conference call. The webcast and the presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event. About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial. HOOKIPA’s non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic hepatitis B infections. Find out more about HOOKIPA online at www.hookipapharma.com. HOOKIPA Forward Looking StatementsCertain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results for HB-101 and other programs, and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA’s ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s quarterly report on Form 10-K for the quarter ended December 31, 2020 which is available on the Security and Exchange Commission’s website at www.sec.gov and HOOKIPA’s website at www.hookipapharma.com. Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website. HOOKIPA Pharma Inc.Consolidated Statements of Operations (Unaudited)(In thousands, except share and per share data) Three months ended December 31, Year ended December 31, 2020 2019 2020 2019 Revenue from collaboration and licensing$5,163 $3,618 $19,584 $11,942 Operating expenses: Research and development (15,688) (11,179) (54,787) (46,312)General and administrative (4,669) (5,664) (18,082) (16,715)Total operating expenses (20,357) (16,843) (72,869) (63,027)Loss from operations (15,194) (13,225) (53,285) (51,085)Total interest, other income and taxes, net 2,719 2,981 9,203 8,048 Net loss$(12,475) $(10,244) $(44,082) $(43,037)Net loss per share — basic and diluted (0.46) (0.40) (1.69) (2.41) Condensed Balance Sheets (Unaudited)(In thousands) As of As of December 31, December 31, 2020 2019Cash, cash equivalents and restricted cash$143,177 $113,575Total assets 187,817 143,745Total liabilities 31,694 25,846Total stockholders’ equity 156,123 117,899 For further information, please contact: MediaInvestorsNina WaibelMatt BeckSenior Director - CommunicationsExecutive Director - Investor [email protected]@hookipapharma.com Media enquiries Instinctif Partners [email protected] +44 (0)20 7457 2020

Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.